Core Viewpoint - NeuroBo Pharmaceuticals, Inc. is undergoing a corporate name change to "MetaVia Inc." and will begin trading under the new Nasdaq ticker symbol "MTVA" effective November 29, 2024, as part of a strategic realignment ahead of significant clinical milestones [1][2][3] Company Overview - NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5] Financial Position - The company remains well-funded following a successful financing round in June 2024, raising up to $70 million in aggregate gross proceeds, which includes $20 million upfront and $50 million in clinical milestone-based warrants [3] Clinical Development - Data from the Phase 2a clinical trial for DA-1241, a GPR119 agonist for MASH treatment, is expected to be reported in December 2024 [4] - Top-line data from the Phase 1 clinical trial of DA-1726, a dual agonist for obesity treatment, is anticipated in the first quarter of 2025 [4] - DA-1726 is believed to have a better tolerability profile compared to currently marketed GLP-1 agonists, potentially making it a best-in-class obesity drug [4]
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases